These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11056834)

  • 1. Reboxetine and treatment-refractory elderly patients with depression.
    Chue P
    Can J Psychiatry; 2000 Sep; 45(7):669. PubMed ID: 11056834
    [No Abstract]   [Full Text] [Related]  

  • 2. Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.
    Künzel HE; Schuld A; Pollmächer T
    Pharmacopsychiatry; 2004 Nov; 37(6):307-8. PubMed ID: 15551201
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
    López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
    Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
    Pintor L; Baillès E; Valldeoriola F; Tolosa E; Martí MJ; de Pablo J
    Gen Hosp Psychiatry; 2006; 28(1):59-64. PubMed ID: 16377367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escitalopram/reboxetine combination in depressed patients with substance use disorder.
    Camarasa X; Lopez-Martinez E; Duboc A; Khazaal Y; Zullino DF
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):165-8. PubMed ID: 15610962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression.
    Linka T; Müller BW; Bender S; Sartory G; Gastpar M
    Pharmacopsychiatry; 2005 May; 38(3):139-43. PubMed ID: 15902586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding studies on reboxetine: a tale of hide and seek.
    Wieseler B; McGauran N; Kaiser T
    BMJ; 2010 Oct; 341():c4942. PubMed ID: 20940211
    [No Abstract]   [Full Text] [Related]  

  • 11. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.
    Rampello L; Alvano A; Chiechio S; Raffaele R; Vecchio I; Malaguarnera M
    Arch Gerontol Geriatr; 2005; 40(3):275-85. PubMed ID: 15814161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.
    Kasper S
    Psychopharmacology (Berl); 2002 Feb; 159(4):445-6. PubMed ID: 11823898
    [No Abstract]   [Full Text] [Related]  

  • 14. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary retention with reboxetine-fluoxetine combination in a young man.
    Benazzi F
    Can J Psychiatry; 2000 Dec; 45(10):936. PubMed ID: 11190365
    [No Abstract]   [Full Text] [Related]  

  • 16. Body dysmorphic disorder treated with bupropion: cases report.
    Nardi AE; Lopes FL; Valença AM
    Aust N Z J Psychiatry; 2005; 39(1-2):112. PubMed ID: 15660717
    [No Abstract]   [Full Text] [Related]  

  • 17. Antidepressants in bipolar depression: when less is more.
    Ruzickova M; Alda M
    J Psychiatry Neurosci; 2002 Jul; 27(4):312. PubMed ID: 12174738
    [No Abstract]   [Full Text] [Related]  

  • 18. Does the clinical course of depression determine improvement in symptoms and quality of life?
    Moses T; Leuchter AF; Cook I; Abrams M
    J Nerv Ment Dis; 2006 Apr; 194(4):241-8. PubMed ID: 16614544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of treatment response in major depression: integration of concepts.
    Mulert C; Juckel G; Brunnmeier M; Karch S; Leicht G; Mergl R; Möller HJ; Hegerl U; Pogarell O
    J Affect Disord; 2007 Mar; 98(3):215-25. PubMed ID: 16996140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
    Feighner JP; Sverdlov L; Hlavka J; Nicolau G; Cartwright K; Freed JS
    Int Clin Psychopharmacol; 2008 Jan; 23(1):29-35. PubMed ID: 18090505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.